Purdue Pharma L.P. to Fund Harm Reduction Therapeutics, Inc.’s Development of Over-the-Counter Opioid Overdose Reversal Medication
Opinion – Steve Miller: Here’s what critics of the Purdue Pharma settlement get wrong; The Washington Post
Oct 27, 2020
If the purpose of litigation against opioid manufacturers is to help address the opioid crisis, then the Justice Department’s resolution of its investigation of Purdue should be hailed as a landmark settlement in the public interest. As victim advocates and public health experts have noted, the settlement can have a significant and positive impact.
When it comes to teens navigating the issue of substance use and substance use disorder, The Children’s Center of Hamden in Connecticut knows that prioritizing realistic progress, offering teens alternatives, and providing the support to seek treatment services – on their own terms – makes all the difference.
How an optimistic problem solver and non-profit CEO is working with community organizations and non-profits to understand their most pressing challenges and connect them with resources to bring solutions to life.
Receiving from Purdue Pharma more than $100 million as part of a settlement of litigation brought by the state, the National Center for Wellness & Recovery (NCWR) at Oklahoma State University is remarkably positioned to accelerate work to address and abate the opioid crisis.